Immunology: the new discovery of immune cells or the development of new anti-cancer therapy

January 15, 2020 / biourn / -- recently, a researcher from University College London, UK, published in the international journal immunology, revealed how a special kind of immune cells can be activated to kill cancerous cells by studying mice Relevant research may help develop new anti-cancer therapies Photo source: Sergio Quezada, researcher of cc0 public domain, said that after immunotherapy, some immune cells, such as some CD4 cells, are traditionally considered to be able to assist or regulate+ T cells become toxic and can kill cancer cells directly Now researchers have revealed the molecular and cellular mechanisms behind their activities Researchers have found that growth factor-il-2 and transcription factor Blimp-1 of T cells are mainly responsible for opening the potential killing activity of CD4 + T cells in cancerous tumors The researchers point out that these immune cells have amazing potential to kill cancer cells, but to maximize their effectiveness, we need to know how the mechanism is activated; this study provides evidence and reasons to use Blimp-1 to make CD4+ To maximize the antitumor activity of T cells, researchers are currently working on the development of new individualized cell therapy, that is, increasing the activity of Blimp-1 to drive potential tumor control T cell is a special kind of lymphocyte, which plays a key role in the process of immune response In immunotherapy, T cell can be modified to resist cancer These cells can "patrol" in the body and look for infected cells to kill them However, T cell does not recognize most of cancer, because cancer comes from the body's own tissue, which is responsible for most of T cells It seems normal, which may bring great challenge to T cell therapy, so researchers need to find new ways to drive T cells to kill cancer cells directly Researcher Karl Professor peggs said that recently, cell therapy has become the mainstream in clinical practice There are still many unknowns about how to optimize these therapies, especially how to improve their therapeutic activity on solid tumor cancer The results of this study can help researchers understand the regulator of T-cell differentiation in depth, thus providing corresponding new elements to help target and enhance the efficacy of therapy Power Such research can also help scientists understand the intricacies of the body's immune system and how it can be used to effectively kill cancer cells Finally, the researchers said that this study provides more and more evidence for the development of new immunotherapy in the later stage, especially the researchers may further study and develop more new treatments for cancer Original source: Anna Ś ledzi ń ska, Maria Vila de Mucha, Katharina bergerhoff, et al Regulatory T cells retrain interleukin-2 - and blimp-1-dependent acquisition of cycloxic function by CD4 + T cells, Immunology (2020) Doi: 10.1016/j.immuni.2019.12.007